Pharma/Fine Chemicals Roundup – August 21

CAMBREX SIGNS API MANUFACTURING DEAL, TO EXPAND PRODUCTION CAPACITY Cambrex (East Rutherford, NJ) says it has entered into an agreement to supply an active pharmaceutical ingredient (API) for a customer's Phase 3 program during 2013–2014. The name of the customer was not disclosed.  Cambrex, under this nonexclusive supply arrangement, will manufacture and deliver Phase 3 and prelaunch quantities of this product candidate. The agreement is expected to contribute over $20 million to Cambrex’s revenues in 2013—and potentially even more in...

This information is only available to Chemical Week subscribers.

Forgot your user ID or password?
Click here to have it sent to you.

Email Address First Name Last Name

Not an IHS Chemical Week 24/7 member yet? Here's why you should be: Searchable online archive access of the last 2 years of Chemical Week. Print or digital magazine subscription Price and market change alerts Economic data and statistics Buyers' Guides Webcasts | whitepapers